ViroStatics CEO, Franco Lori, MD, Presents Late Breaker on Novel AV-HALT HIV Therapy at the 2011 International AIDS Society Pathogenesis Conference

SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--Franco Lori, MD, CEO of ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, today presented an oral ‘late breaker’ on the Company’s novel AV-HALT platform at the world’s largest open scientific conference on HIV/AIDS – the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome. Held every two years, the conference provides a unique opportunity for the world’s leading scientists, clinicians, public health experts and community leaders to examine the latest developments in HIV-related research.